-
Innovation Ranking
NewInnovation Ranking – Spero Therapeutics Inc
Spero Therapeutics Inc. (Spero) is a clinical-stage biopharmaceutical company. It is engaged in developing, identifying and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. Its product pipeline includes SPR994 oral gram-negative program, SPR741and SPR206 IV potentiator platform, and SPR720 non-tuberculosis mycobacterium. The company markets its products through third party distributors. Its partners include U.S. National Institute of Allergy and Infectious Diseases (NIAID), U.S. Department of Defense (DoD) and Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Spero is headquartered in...
-
Product Insights
Mycobacterium avium Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycobacterium avium Infections - Drugs In Development, 2023’, provides an overview of the Mycobacterium avium Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycobacterium avium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pyelonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Pyelonephritis - Drugs In Development, 2023’, provides an overview of the Pyelonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Klebsiella Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Klebsiella Infections - Drugs In Development, 2023’, provides an overview of the Klebsiella Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Klebsiella Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Escherichia coli Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Escherichia coli Infections - Drugs In Development, 2023’, provides an overview of the Escherichia coli Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Klebsiella pneumoniae Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Klebsiella pneumoniae Infections - Drugs In Development, 2023’, provides an overview of the Klebsiella pneumoniae Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Acinetobacter Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Acinetobacter Infections - Drugs In Development, 2023’, provides an overview of the Acinetobacter Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Urinary Tract Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Tract Infections - Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Mycobacterium tuberculosis Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycobacterium tuberculosis Infections - Drugs In Development, 2023’, provides an overview of the Mycobacterium tuberculosis Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycobacterium tuberculosis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Tuberculosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Tuberculosis - Drugs In Development, 2023’, provides an overview of the Tuberculosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...